Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME?
G Al-Khadairi, J Decock - Cancers, 2019 - mdpi.com
PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis
antigen (CTA) with restricted expression in somatic tissues and re-expression in various …
antigen (CTA) with restricted expression in somatic tissues and re-expression in various …
Preferentially expressed antigen in melanoma is a multifaceted cancer testis antigen with diverse roles as a biomarker and therapeutic target
M Bose - International Journal of Translational Medicine, 2023 - mdpi.com
Preferentially expressed antigen in melanoma (PRAME) is a cancer testis antigen (CTA) that
is selectively expressed in certain somatic tissues, predominantly in the testis, and is …
is selectively expressed in certain somatic tissues, predominantly in the testis, and is …
Clinicopathological and prognostic significance of PRAME overexpression in human cancer: a meta‐analysis
J Li, J Yin, J Zhong, Z Yang, A Tang… - BioMed research …, 2020 - Wiley Online Library
Numerous studies have demonstrated that preferentially expressed antigen in melanoma
(PRAME) is abnormally expressed in various solid tumours. However, the …
(PRAME) is abnormally expressed in various solid tumours. However, the …
PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival
Background Immunohistochemistry‐based protein biomarkers can provide useful prognostic
information in cutaneous melanoma. The independent prognostic value of Ki‐67 has been …
information in cutaneous melanoma. The independent prognostic value of Ki‐67 has been …
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
G Al-Khadairi, A Naik, R Thomas, B Al-Sulaiti… - Journal of translational …, 2019 - Springer
Background The triple negative breast cancer (TNBC) paradox marks a major challenge in
the treatment-decision making process. TNBC patients generally respond better to …
the treatment-decision making process. TNBC patients generally respond better to …
Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors
A Šafanda, M Kendall Bártů, R Michálková, I Stružinská… - Virchows Archiv, 2023 - Springer
Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen
selectively expressed in somatic tissues and various solid malignant tumors and is …
selectively expressed in somatic tissues and various solid malignant tumors and is …
Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
A Naik, R Thomas, G Al‐Khadairi… - Journal of Cellular …, 2021 - Wiley Online Library
Abstract PReferentially expressed Antigen in Melanoma (PRAME) is a cancer testis antigen
with restricted expression in somatic tissues and re‐expression in poor prognostic solid …
with restricted expression in somatic tissues and re‐expression in poor prognostic solid …
The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas
Abstract PRAME and NY-ESO-1 are cancer-testis antigens (CTAs) reported to be highly
enriched in triple-negative breast cancers (TNBCs), against which vaccines and …
enriched in triple-negative breast cancers (TNBCs), against which vaccines and …
PRAME is critical for breast cancer growth and metastasis
Z Sun, Z Wu, F Zhang, Q Guo, H Chen, J Zhao, D Song… - Gene, 2016 - Elsevier
Breast cancer is the most common cause of cancer death in women and ranks second
among cancer deaths. Metastasis is the main cause of death in breast cancer patients …
among cancer deaths. Metastasis is the main cause of death in breast cancer patients …
PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions—a comprehensive clinicopathologic …
This study examined PRAME (preferentially expressed antigen in melanoma) expression by
immunohistochemistry and reverse transcription quantitative PCR (RT-qPCR) in 202 …
immunohistochemistry and reverse transcription quantitative PCR (RT-qPCR) in 202 …